Therefore, we performed a meta-analysis of published studies to assess the impact of K-ras and PIK3CA mutation on the ORR, progression-free survival (PFS), and overall survival (OS) of NSCLC patients treated with EGFR-TKIs to clarify whether these mutations attenuate the clinical benefits of EGFR-TKI treatment in NSCLC patients. Here, KRAS is linked to non-small cell lung carcinoma.